127 related articles for article (PubMed ID: 2124500)
1. Bioavailability of subcutaneous ifosfamide and feasibility of continuous outpatient application in cancer patients.
Cerny T; Küpfer A; Zeugin T; Brunner KW
Ann Oncol; 1990 Sep; 1(5):365-8. PubMed ID: 2124500
[TBL] [Abstract][Full Text] [Related]
2. Subcutaneous continuous infusion of ifosfamide and cyclophosphamide in ambulatory cancer patients: bioavailability and feasibility.
Cerny T; Graf A; Rohner P; Zeugin T; Brunner KW; Küpfer A
J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S129-34. PubMed ID: 1795001
[TBL] [Abstract][Full Text] [Related]
3. Ambulatory high-dose 5-day continuous-infusion ifosfamide combination chemotherapy in advanced solid tumors: a feasibility study.
Loeffler TM; Weber FW; Hausamen TU
J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S125-8. PubMed ID: 1795000
[TBL] [Abstract][Full Text] [Related]
4. Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas.
Skubitz KM; Hamdan H; Thompson RC
Cancer; 1993 Nov; 72(10):2963-9. PubMed ID: 8221562
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule.
Serrone L; Zeuli M; Gamucci T; Nardi M; Cognetti F
Cancer Chemother Pharmacol; 2001 Mar; 47(3):206-10. PubMed ID: 11320663
[TBL] [Abstract][Full Text] [Related]
6. Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics.
Boddy AV; English M; Pearson AD; Idle JR; Skinner R
Eur J Cancer; 1996 Jun; 32A(7):1179-84. PubMed ID: 8758250
[TBL] [Abstract][Full Text] [Related]
7. Ifosfamide in the treatment of soft-tissue sarcomas: experience at the West German Tumor Center, Essen.
Schütte J; Kellner R; Seeber S
Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S194-8. PubMed ID: 8453697
[TBL] [Abstract][Full Text] [Related]
8. Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients.
Coriat R; Mir O; Camps S; Ropert S; Billemont B; Leconte M; Larousserie F; Anract P; Alexandre J; Goldwasser F
Cancer Chemother Pharmacol; 2010 Feb; 65(3):491-5. PubMed ID: 19588140
[TBL] [Abstract][Full Text] [Related]
9. Continuous 5-day infusion of ifosfamide with mesna in inoperable pancreatic cancer patients: a phase II study.
Cerny T; Martinelli G; Goldhirsch A; Terrier F; Joss R; Fey MF; Brunner KW; Küpfer A
J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S135-8. PubMed ID: 1795002
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of ifosfamide administered according to three different schedules in metastatic soft tissue and bone sarcomas.
Comandone A; Leone L; Oliva C; Frustaci S; Monteleone M; Colussi AM; Dal Canton O; Bergnolo P; Boglione A; Bumma C
J Chemother; 1998 Oct; 10(5):385-93. PubMed ID: 9822357
[TBL] [Abstract][Full Text] [Related]
11. High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible?
De Pas T; De Braud F; Orlando L; Nolè F; Munzone E; Zampino MG; Fazio N; Aapro MS; Goldhirsch A
Ann Oncol; 1998 Aug; 9(8):917-9. PubMed ID: 9789617
[TBL] [Abstract][Full Text] [Related]
12. Feasibility trial of high-dose 7-day continuous-infusion ifosfamide given on an outpatient basis.
Bellmunt J; Eres N; Ribas A; Casado S; Albanell J; Baselga J
Cancer Chemother Pharmacol; 1997; 40(3):273-6. PubMed ID: 9219513
[TBL] [Abstract][Full Text] [Related]
13. Dosing and side-effects of ifosfamide plus mesna.
Brade WP; Herdrich K; Kachel-Fischer U; Araujo CE
J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S164-86. PubMed ID: 1795007
[TBL] [Abstract][Full Text] [Related]
14. Mesna: continuous or bolus infusion?
Willemse PH; de Vries EG
J Clin Oncol; 1989 Jun; 7(6):817-9. PubMed ID: 2497231
[No Abstract] [Full Text] [Related]
15. Dose finding of ifosfamide administered with a chronic two-week continuous infusion.
Cartei G; Clocchiatti L; Sacco C; Pella N; Bearz A; Mantero J; Pastorelli D; Salmaso F; Zustovich F
Oncology; 2003; 65 Suppl 2():31-6. PubMed ID: 14586144
[TBL] [Abstract][Full Text] [Related]
16. Ifosfamide, vincristine, doxorubicin and dacarbazine in adult patients with advanced soft-tissue sarcoma.
Wiklund TA; Blomqvist CP; Virolainen M; Elomaa I
Cancer Chemother Pharmacol; 1992; 30(2):100-4. PubMed ID: 1600589
[TBL] [Abstract][Full Text] [Related]
17. Full-dose ifosfamide can be safely administered to outpatients.
Meazza C; Bisogno G; Casanova M; Zanetti I; Carli M; Ferrari A
Pediatr Blood Cancer; 2008 Feb; 50(2):375-8. PubMed ID: 16847930
[TBL] [Abstract][Full Text] [Related]
18. Ifosfamide and epirubicin combination in untreated sarcomas: two treatment schedules.
Serrone L; Zeuli M; Papaldo P; Nardoni C; Pacetti U; Cognetti F
Onkologie; 2001 Oct; 24(5):465-8. PubMed ID: 11694773
[TBL] [Abstract][Full Text] [Related]
19. Intermittent continuous infusion of ifosfamide and 5-fluorouracil in patients with advanced adenocarcinoma of the pancreas.
Poorter RL; Bakker PJ; Huizing MT; Taat CW; Rietbroek RC; Gouma DJ; Rauws EA; Veenhof CH
Ann Oncol; 1995 Dec; 6(10):1048-9. PubMed ID: 8750159
[TBL] [Abstract][Full Text] [Related]
20. Ambulatory treatment with 5 days continuous venous infusion of ifosfamide for advanced colorectal cancer: a phase II feasibility study.
Focan C; Kreutz F; Levi F
Anticancer Drugs; 1993 Aug; 4(4):459-62. PubMed ID: 8400348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
